This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Regulation on Veterinary Medicinal Products | |
|---|---|
| Name | Regulation on Veterinary Medicinal Products |
| Jurisdiction | International, regional, national |
| Subject | Veterinary pharmacology, animal health law |
Regulation on Veterinary Medicinal Products
Regulation on Veterinary Medicinal Products governs authorization, manufacture, distribution, use, and surveillance of medicines for animals, balancing animal health, World Health Organization priorities, Food and Agriculture Organization of the United Nations objectives, and public health safeguards. It aligns with standards from bodies such as the European Medicines Agency, United States Food and Drug Administration, and World Organisation for Animal Health while interacting with trade frameworks like the World Trade Organization and legal instruments exemplified by the Treaty of Lisbon. Regulatory regimes reflect inputs from stakeholders including the International Federation for Animal Health, veterinary associations such as the World Veterinary Association, and pharmaceutical firms like Zoetis and Bayer AG.
Regulation covers medicinal products for companion animals, livestock, and aquaculture, intersecting with agencies like the European Commission, United States Department of Agriculture, and Health Canada. It addresses product categories regulated by statutes such as the Medicines Act 1968 style frameworks, veterinary biologics overseen by institutions like the Pirbright Institute, and antimicrobial stewardship initiatives influenced by reports from the O'Neill review and Codex Alimentarius Commission. Scope includes residues in food chain contexts governed by standards from the Joint FAO/WHO Expert Committee on Food Additives and trade considerations under the Agreement on Technical Barriers to Trade.
National law frameworks derive from constitutive texts and statutes modeled on instruments such as the European Union Veterinary Directive and the Federal Food, Drug, and Cosmetic Act where applicable. International standards and guidelines come from the World Organisation for Animal Health (OIE), Codex Alimentarius Commission, and harmonization efforts by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use when extended to veterinary contexts. Bilateral and regional arrangements—examples include the North American Free Trade Agreement negotiations and the Comprehensive and Progressive Agreement for Trans-Pacific Partnership—affect cross-border authorization and pharmacovigilance cooperation. Intellectual property regimes overseen by the World Intellectual Property Organization and patent offices such as the United States Patent and Trademark Office influence market exclusivity and generic entry.
Authorization pathways mirror models used by the European Medicines Agency, U.S. Food and Drug Administration Center for Veterinary Medicine, and national competent authorities like the Medicines and Healthcare products Regulatory Agency. Dossier requirements reference guidelines from the International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products and typically include safety, efficacy, and quality modules paralleling the Common Technical Document format. Special procedures—conditional approval, minor use/minor species schemes, and emergency authorizations—reflect precedents set during crises addressed by the European Centre for Disease Prevention and Control and national emergency statutes such as those invoked after outbreaks like the 2001 United Kingdom foot-and-mouth outbreak.
Manufacturing controls require compliance with Good Manufacturing Practice standards enforced by inspectorates like the Medicines and Healthcare products Regulatory Agency and the Pharmaceutical Inspection Co-operation Scheme. Quality control testing references pharmacopoeial monographs from the United States Pharmacopeia, European Pharmacopoeia, and national pharmacopoeias administered by institutions like the National Institute for Biological Standards and Control. Facility licensing and batch release procedures resemble practices at biologics centers such as Staten Serum Institute, while supply chain integrity leverages guidance from the International Air Transport Association and security frameworks influenced by the Wassenaar Arrangement in dual-use contexts.
Post-market surveillance systems are structured akin to the Yellow Card scheme and the FDA Adverse Event Reporting System, with databases managed by regional centers such as the European Medicines Agency Pharmacovigilance Risk Assessment Committee. Signal detection and risk management plans draw on methodologies used by the Council for International Organizations of Medical Sciences and analytical practices from regulatory science programs at institutions like the National Institutes of Health. Reporting duties involve veterinarians, manufacturers, and laboratories including reference labs like the OIE Reference Laboratories, and connect to antimicrobial resistance monitoring under networks like the Global Antimicrobial Resistance Surveillance System.
Controls over supply chains, prescription status, and over-the-counter availability interact with professional rules from bodies like the Royal College of Veterinary Surgeons, veterinary formularies such as those published by the British Veterinary Association, and pharmacy regulations enforced by organizations like the American Pharmacists Association. Feed additive oversight ties into mandates by the European Food Safety Authority and commodity standards administered by the International Feed Industry Federation. Use restrictions—withdrawal periods, residue limits, and off-label directives—implement tolerances established by the Codex Alimentarius Commission and national food safety agencies such as the Food Safety and Standards Authority of India.
Enforcement mechanisms employ inspection powers and sanctions modeled on practices of the European Court of Justice and administrative systems like those used by the U.S. Department of Justice for regulatory violations. Penalties range from market withdrawals and recalls coordinated with agencies such as the Centers for Disease Control and Prevention in zoonotic contexts, to criminal prosecutions assisted by prosecutors from institutions like the Crown Prosecution Service. Compliance promotion leverages guidance from trade bodies like the International Federation of Pharmaceutical Manufacturers & Associations and capacity-building programs by donors including the World Bank and United Nations Development Programme.
Category:Veterinary medicine